Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Mar
30
2023
Medical Device Developers Now Required to Incorporate Cybersecurity Plans into FDA Premarket Submissions for “Cyber” Devices Mintz
Mar
30
2023
Food and Chemicals Unpacked: Laying Claim: FTC’s Green Guides Keller and Heckman LLP
Mar
30
2023
Use of Salt Substitutes Expanded to Help Lower Sodium Intake Keller and Heckman LLP
Mar
30
2023
The South Korean Food Authority Releases New Rules and Policies Supporting the Development of the Alternative Protein Industry Keller and Heckman LLP
Mar
30
2023
The Short-Term Consequences of Alabama’s Cannabis Social Equity Policy Bradley Arant Boult Cummings LLP
Mar
29
2023
FDA Publishes Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market Keller and Heckman LLP
Mar
29
2023
FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2023
The BioPharma Patent Cliff: 2023 and Beyond Foley & Lardner LLP
Mar
28
2023
FDA Revamps Guidance Concerning Use of Electronic Systems, Records, and Signatures in Clinical Investigations Nelson Mullins
Mar
28
2023
De-scheduling vs. Re-scheduling Marijuana: A Dramatic Difference Bradley Arant Boult Cummings LLP
Mar
28
2023
FSIS Proposes New Rules Regarding U.S. Origin Claims Keller and Heckman LLP
Mar
28
2023
Weeding Out Employees: The Ups and Downs of Drug-Testing Manufacturing Workforce Jackson Lewis P.C.
Mar
28
2023
Technical Effect Embodied In Technical Teaching K&L Gates
Mar
27
2023
FDA Issues Draft Guidance on Dietary Guidance Statements on Food Labels Keller and Heckman LLP
Mar
27
2023
Last Dance with Mary Jane? Faltering Cannabis Businesses May Have a Bankruptcy Option in Addition to State Law Remedies Bradley Arant Boult Cummings LLP
Mar
25
2023
EC Committee Issues Final Opinion on Hydroxyapatite (Nano) in Oral Cosmetic Products Bergeson & Campbell, P.C.
Mar
24
2023
Judge Approves $25M Settlement of Antitrust Action Against J&J for Allegedly Blocking Biosimilars MoginRubin
Mar
24
2023
Pfizer Expands Cancer Drug Portfolio with $43 Billion Biotech Acquisition MoginRubin
Mar
23
2023
APHIS Accepting Public Comments on Draft Guide for Submitting Permit Applications for Microorganisms Developed using Genetic Engineering Bergeson & Campbell, P.C.
Mar
23
2023
California Assembly Members Introduce Bill to Ban Certain Color Additives Keller and Heckman LLP
Mar
23
2023
FDA Revises Recommendations Regarding Electronic Systems, Records, and Signatures in Clinical Investigations Nelson Mullins
Mar
23
2023
Is the Access to Medical Marijuana a Fundamental Right? Bradley Arant Boult Cummings LLP
Mar
22
2023
Big Law Redefined: Episode 3 | Beauty Trends in a Post-Pandemic World [PODCAST] Greenberg Traurig, LLP
Mar
22
2023
Recent Employment Law Updates in the District of Columbia Mintz
Mar
22
2023
This Week in 340B: March 14 – 20, 2023 McDermott Will & Emery
Mar
22
2023
New Report Outlines FDA’s Strategy to Ensure the Safety of Imported Seafood Keller and Heckman LLP
Mar
22
2023
Building Biotech with Brains: Strategies for Maximizing Value of AI-Driven Biotechnology Inventions Foley & Lardner LLP
Mar
21
2023
California’s Toxic-Free Cosmetics Act Bans 24 Ingredients From Cosmetic Products Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins